PMID- 35228756
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20221024
IS  - 1804-7521 (Electronic)
IS  - 1213-8118 (Linking)
VI  - 166
IP  - 3
DP  - 2022 Sep
TI  - A rare epidermal growth factor receptor (EGFR) gene mutation in small cell lung 
      carcinoma patients.
PG  - 274-279
LID - 10.5507/bp.2022.007 [doi]
AB  - AIM: Activating mutations in the epidermal growth factor receptor (EGFR) are 
      predominantly detected in pulmonary adenocarcinoma and have been reported in 
      small cell lung cancer (SCLC) for decades. This retrospective single-center study 
      aimed to determine the frequency and types of EGFR mutations in SCLC in Taiwan. 
      METHODS: This study comprises a consecutive cohort of 161 patients histologically 
      diagnosed with SCLC between January 1992 and August 2014 at the Department of 
      Pathology in Keelung Chang Gung Memorial Hospital, Taiwan. Archived 
      formalin-fixed paraffin-embedded sections from 71 patients were eligible for 
      molecular analysis. EGFR mutation analysis was performed using a fully-automated 
      IdyllaTM EGFR Mutation Test and confirmed a comparable result through Qiagen 
      Therascreen(R) EGFR RGQ PCR. In addition, EGFR gene copy number was assessed in 
      EGFR-mutated tumors by fluorescence in situ hybridization (FISH). RESULTS: 
      Mutational status of the EGFR gene was successfully analyzed in 63 specimens by 
      both IdyllaTM and Qiagen platforms. Both methods detected L858R point mutation in 
      exon 21 in an 81-year-old female and a 47-year-old male non-smoker. Both tumors 
      show no concurrent EGFR gene amplification. The overall agreement between results 
      obtained with the Idylla EGFR Mutation Test and Qiagen Therascreen(R) EGFR RGQ PCR 
      was 100% Conclusions. Our results showed that EGFR mutation is a rare mutation 
      type in a consecutive series of de novo SCLC. Furthermore, the performance of 
      Idylla EGFR Mutation Test and Qiagen Therascreen(R) EGFR RGQ PCR on archived 
      paraffin sections of limited quantities is available with the high agreement of 
      results.
FAU - Hwang, Cheng-Cheng
AU  - Hwang CC
AD  - Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
AD  - College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.
FAU - Hsieh, Tsan-Yu
AU  - Hsieh TY
AD  - Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
AD  - College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.
FAU - Yeh, Kun-Yang
AU  - Yeh KY
AD  - College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.
AD  - Department of Oncology and Hematology, Division of Medicine, Keelung Chang Gung 
      Memorial Hospital, Keelung, Taiwan.
FAU - Chen, Tzu-Ping
AU  - Chen TP
AD  - College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.
AD  - Department of Thoracic and Cardiovascular Surgery, Keelung Chang Gung Memorial 
      Hospital, Keelung, Taiwan.
FAU - Hua, Chung-Ching
AU  - Hua CC
AD  - College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.
AD  - Department of Thoracic Medicine, Division of Medicine, Keelung Chang Gung 
      Memorial Hospital, Keelung, Taiwan.
FAU - Chang, Liang-Che
AU  - Chang LC
AD  - Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
AD  - College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.
FAU - Chen, Jim-Ray
AU  - Chen JR
AD  - Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
AD  - College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220218
PL  - Czech Republic
TA  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
JT  - Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, 
      Czechoslovakia
JID - 101140142
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - 1HG84L3525 (Formaldehyde)
RN  - 8002-74-2 (Paraffin)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis
MH  - DNA Mutational Analysis/methods
MH  - *ErbB Receptors/genetics
MH  - Formaldehyde
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/diagnosis
MH  - Mutation
MH  - Paraffin
MH  - Retrospective Studies
MH  - *Small Cell Lung Carcinoma/diagnosis/genetics
OTO - NOTNLM
OT  - IdyllaTM
OT  - epidermal growth factor receptor
OT  - gene amplification
OT  - gene mutation
OT  - small cell lung cancer
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/03/02 06:00
MHDA- 2022/09/21 06:00
CRDT- 2022/03/01 05:57
PHST- 2021/12/08 00:00 [received]
PHST- 2022/02/07 00:00 [accepted]
PHST- 2022/03/02 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/03/01 05:57 [entrez]
AID - 10.5507/bp.2022.007 [doi]
PST - ppublish
SO  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Sep;166(3):274-279. 
      doi: 10.5507/bp.2022.007. Epub 2022 Feb 18.